Structure, function, and recombinant production of EGFL7
Author:
McDonald Brennan1ORCID, Schmidt Mirko H. H.1
Affiliation:
1. 9169 Institute of Anatomy, Medical Faculty Carl Gustav Carus, Technische Universität Dresden School of Medicine , Fetscherstr. 74 , D-01307 Dresden , Germany
Abstract
Abstract
The secreted factor Epidermal growth factor-like protein 7 (EGFL7) is involved in angiogenesis, vasculogenesis, as well as neurogenesis. Importantly, EGFL7 is also implicated in various pathological conditions, including tumor angiogenesis in human cancers. Thus, understanding the mechanisms through which EGFL7 regulates and promotes blood vessel formation is of clear practical importance. One principle means by which EGFL7’s function is investigated is via the expression and purification of the recombinant protein. This mini-review describes three methods used to produce recombinant EGFL7 protein. First, a brief overview of EGFL7’s genetics, structure, and function is provided. This is followed by an examination of the advantages and disadvantages of three common expression systems used in the production of recombinant EGFL7; (i) Escherichia coli (E. coli), (ii) human embryonic kidney (HEK) 293 cells or other mammalian cells, and (iii) a baculovirus-based Sf9 insect cell expression system. Based on the available evidence, we conclude that the baculovirus-based Sf9 insect cell expression currently has the advantages of producing active recombinant EGFL7 in the native conformation with the presence of acceptable posttranslational modifications, while providing sufficient yield and stability for experimental purposes.
Publisher
Walter de Gruyter GmbH
Reference66 articles.
1. Barth, K., Vasić, V., McDonald, B., Heinig, N., Wagner, M.-C., Schumann, U., Röhlecke, C., Bicker, F., Schumann, L., Radyushkin, K., et al.. (2023). EGFL7 loss correlates with increased VEGF-D expression, upregulating hippocampal adult neurogenesis and improving spatial learning and memory. Cell. Mol. Life Sci. 80: 54, https://doi.org/10.1007/s00018-023-04685-z. 2. Bicker, F. and Schmidt, M.H.H. (2010). EGFL7: a new player in homeostasis of the nervous system. Cell Cycle 9: 1263–1269, https://doi.org/10.4161/cc.9.7.11091. 3. Bicker, F., Vasic, V., Horta, G., Ortega, F., Nolte, H., Kavyanifar, A., Keller, S., Stankovic, N.D., Harter, P.N., Benedito, R., et al.. (2017). Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception. Nat. Commun. 8: 1, https://doi.org/10.1038/ncomms15922. 4. Bill, M., Pathmanathan, A., Karunasiri, M., Shen, C., Burke, M.H., Ranganathan, P., Papaioannou, D., Zitzer, N.C., Snyder, K., LaRocco, A., et al.. (2020). EGFL7 antagonizes NOTCH signaling and represents a novel therapeutic target in acute myeloid leukemia. Clin. Cancer Res. 26: 669–678, https://doi.org/10.1158/1078-0432.CCR-19-2479. 5. Bras, A.L., Samson, C., Trentini, M., Caetano, B., Lelievre, E., Mattot, V., Beermann, F., and Soncin, F. (2010). VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2. PLoS One 5: e12156, https://doi.org/10.1371/journal.pone.0012156.
|
|